What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Myocardial infarction
- Surgery
His primary scientific interests are in Internal medicine, Myocardial infarction, Cardiology, Surgery and Angioplasty.
Percutaneous coronary intervention, Randomized controlled trial, Stroke, Aspirin and Unstable angina are the subjects of his Internal medicine studies.
His Myocardial infarction research integrates issues from Coronary artery disease and Anesthesia.
His study brings together the fields of Mortality rate and Cardiology.
The Surgery study combines topics in areas such as Gastroenterology, Placebo and Tissue plasminogen activator.
In his study, Pathology is strongly linked to Restenosis, which falls under the umbrella field of Angioplasty.
His most cited work include:
- An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. (3240 citations)
- Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. (2731 citations)
- Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events (2298 citations)
What are the main themes of his work throughout his whole career to date?
Eric J. Topol mainly focuses on Internal medicine, Cardiology, Myocardial infarction, Surgery and Angioplasty.
Internal medicine is a component of his Percutaneous coronary intervention, Revascularization, Coronary artery disease, Abciximab and Unstable angina studies.
His Cardiology research includes elements of Restenosis and Percutaneous.
Eric J. Topol focuses mostly in the field of Myocardial infarction, narrowing it down to matters related to Randomized controlled trial and, in some cases, Clinical trial.
Eric J. Topol frequently studies issues relating to Placebo and Surgery.
His Angioplasty research includes elements of Artery, Bypass surgery, Balloon and Atherectomy.
He most often published in these fields:
- Internal medicine (67.18%)
- Cardiology (56.88%)
- Myocardial infarction (48.18%)
What were the highlights of his more recent work (between 2011-2021)?
- Internal medicine (67.18%)
- MEDLINE (3.45%)
- Health care (3.26%)
In recent papers he was focusing on the following fields of study:
Eric J. Topol mainly investigates Internal medicine, MEDLINE, Health care, Genetics and Cardiology.
His Surgery research extends to Internal medicine, which is thematically connected.
Eric J. Topol regularly links together related areas like Bioinformatics in his MEDLINE studies.
The Genetics study which covers Disease that intersects with Clinical psychology.
His Cardiology research is mostly focused on the topic Myocardial infarction.
Myocardial infarction is closely attributed to Pathology in his research.
Between 2011 and 2021, his most popular works were:
- High-performance medicine: the convergence of human and artificial intelligence (972 citations)
- Prevalence of Asymptomatic SARS-CoV-2 Infection. (904 citations)
- The personal and clinical utility of polygenic risk scores. (434 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Myocardial infarction
- Surgery
Health care, MEDLINE, Personalized medicine, Genetic testing and Internal medicine are his primary areas of study.
His Health care study also includes fields such as
- Medical record and Randomized controlled trial most often made with reference to Medical emergency,
- Disease management which connect with Connected health, Glucose meter, Intervention, Receipt and Health management system.
He has included themes like Telemedicine, Bioinformatics and Medical education in his MEDLINE study.
His research in Personalized medicine intersects with topics in Test and Genome-wide association study.
His work deals with themes such as CYP2C19 and Cardiology, which intersect with Internal medicine.
His Clopidogrel research entails a greater understanding of Myocardial infarction.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
